Leading medical provider awarded prestigious European radiation safety ranking

Amsterdam —June 11, 2018 — Affidea, the leading European provider of diagnostic imaging, outpatient and cancer care services, announces that 11 of its centers have been awarded "5 Stars" on the EuroSafe Wall by the European Society of Radiology. This is in recognition of the company's ability to deliver excellence in radiation protection and patient safety.Today’s announcement means that 31 percent of the centers that have been awarded the full “5 Stars” by the European Society of Radiology are run by Affidea. These centers are located in Croatia, Greece, Hungary, Italy, Lithuania, and Turkey.EuroSafe Imaging is the European Society of Radiology’s flagship initiative to promote quality and safety in medical imaging. It is designed to identify and recognise imaging facilities that embody best practice in radiation protection.Imaging facilities are awarded up to five stars depending on the number of criteria of a certain level they fulfil. After successful evaluation, the participating imaging departments are listed on the “Wall of Stars” according to the level attained.The 11 Affidea centers awarded the full “5 Stars” are as follows:1.         Affidea Čavka,  Zagreb, CROATIA2.         Affidea Centro Polidiagnostico Montesanto, Cornaredo, ITALY3.         Affidea Villa Salute, Manerbio, ITALY4.         Azienda Ospedaliero-Universitaria Meyer, Florence, ITALY5.         Affidea Siauliu, LITHUANIA6.         Beykoz State Hospital, Istanbul, TURKEY7.         Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, TURKEY8.         SBU Fatih Sultan Mehmet Training and Research Hospital, Istanbul, TURKEY9.         SBU Haydarpasa Numune Training and Research Hospital, Istanbul, TURKEY10.     SBU Sehit Prof.Dr.Ilhan Varank Sancaktepe Training and Research Hospital, Istanbul, TURKEY11.     SBU Umraniye Training and Research Hospital, Istanbul, TURKEYCommenting on the award, Giuseppe Recchi, Chief Executive Officer of the Affidea Group, said:“As a leading medical provider, we want to make healthcare better, for everyone, saving people´s lives, using state of the art technology safely, effectively and efficiently.This is a prestigious award for our 11 centers and is a testament to the way in which Affidea is delivering clinical excellence in radiation protection, with patient safety as priority.  Through the scale of our network, our digital and hi-tech capabilities and recognized commitment to international awarded clinical excellence, Affidea continues to be the preferred provider for our patients, doctors, private and public insurers.Commenting on how Affidea is continuing to prioritise patient safety, Prof. Rowland Illing, Chief Medical Officer of the Affidea Group, said:“Affidea has put in place the highest standards and procedures to protect patients’ wellbeing and secure the best possible medical outcome. Our company-wide Dose Excellence Campaign to make our CT scans as safe as possible makes us an innovator in diagnostic imaging, having a unique program across Europe which brought us international recognition from prestigious academic and medical societies.We use world class medical equipment, which is rigorously tested by medical professionals, we track patients’ dose and we train our staff to optimise the CT protocol parameters to deliver the right amount of dose for patient’s safety, without compromising image quality.”     About Affidea GroupAffidea (www.affidea.com) is the leading European provider of diagnostic imaging, outpatient and cancer care services, operating in 16 countries across Europe, with a focus on delivering timely, through diagnoses and high quality treatments by working only with state-of-the-art technology and experienced medical professionals. The Affidea Group employs over 7500 professionals and operates over 1250 diagnosis and cancer care modalities with almost 13 million diagnostic examinations every year. Affidea is owned by interests associated with the Bertarelli family which are advised by their business enterprise, Waypoint Capital. (www.waypointcapital.net).For more information on the EuroSafe Imaging initiative, please visit: www.eurosafeimaging.org For more information about Affidea, please contact:Oana Dumitroiu, Head of Brand & CommunicationM: +40 741 036 998 Ed McRandal, Lexington CommunicationsT: +44 207 025 2362 

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.